Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, First Session, on Examining Food and Drug Administration Follow-on Biologics, Generally Referred to as A Biotechnology-derived Protein Drug (or Biologic) That Is Comparable to A Novel, Previously Approved Biologic and That Is Approved With Less Supporting Data Than the Innovator Biologic, March 8, 2007